Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival
A. Vallet(Hôpital Saint-Louis), Brigitte Dréno(Nantes Université), Bastien Oriano(Hôtel-Dieu de Paris), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Célèste Lebbé(Inserm), S. Dalac(CHU Dijon Bourgogne), Jean‐Philippe Arnault(Centre Hospitalier Universitaire Amiens-Picardie), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), F. Granel‐Brocard(Centre Hospitalier Régional et Universitaire de Nancy), F. Brunet‐Possenti(Inserm), E. Maubec(Inserm), F. Aubin(Centre Hospitalier Universitaire de Besançon), Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), B. Guillot(Université de Montpellier), Clara Allayous(Inserm), Raphaël Porcher(Hotel Dieu Hospital), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), Pierre‐Emmanuel Stoebner(Centre Hospitalier Universitaire de Nîmes)
Cited by 10
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k